Back to results
US 12,285,480 B2Granted
Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
AssigneeNantCell, Inc.
InventorsAdrian Rice, Mohit Verma
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for inducing immunity against a severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV2) in a patient in need thereof. The method comprises administering a vaccine composition comprising a self-adjuvanted SARS-CoV2 Spike (S) RNA-based vaccine (AAHI-SC2), followed by administering a replication defective adenovirus (hAd5) vaccine composition, wherein the adenovirus comprises an E1 gene region deletion and an E2b gene region deletion.
Claims16
A method of inducing immunity against an antigen in a patient, the method comprising:
- administering a vaccine composition comprising a self-adjuvanted RNA-based vaccine, wherein the RNA encodes a SARS-CoV-2 spike (S) protein;
- and
- administering a replication defective adenovirus (hAd5) vaccine composition, wherein the adenovirus comprises an E1 gene region deletion and an E2b gene region deletion, and wherein the hAd5 comprises a nucleotide encoding 1) a SARS-CoV-2 S protein having the amino acid sequence of SEQ ID NO:6;
- and 2) a chimeric protein comprising a SARS-CoV-2 nucleocapsid (N) protein and an endosomal targeting sequence (ETSD), wherein the chimeric protein has the amino acid sequence of SEQ ID NO:
- 2.
2 more elements
Dependencies are inferred from the claim text.